Related Experiment Video
Updated: Jun 12, 2026
04:44
Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
Published on: June 16, 2020
Systemic sclerosis-associated interstitial lung disease-proposed recommendations for future randomized clinical
Dinesh Khanna1, Kevin K Brown, Philip J Clements
1Division of Rheumatology, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA. dkhanna@mednet.ucla.edu
Clinical and Experimental Rheumatology
|June 26, 2010
Summary
Systemic sclerosis (SSc) patients often suffer from pulmonary disease. This review offers recommendations for designing future clinical trials targeting SSc-associated interstitial lung disease (SSc-ILD) therapies.
Area of Science:
- Pulmonology
- Rheumatology
- Clinical Trial Design
Background:
- Pulmonary disease is a major cause of death in systemic sclerosis (SSc).
- Recent clinical trials have improved understanding of outcome measures and design for SSc-associated interstitial lung disease (SSc-ILD).
- New insights into SSc-ILD pathogenesis are driving interest in targeted therapies.
Purpose of the Study:
- To propose evidence-based recommendations for the design of future clinical studies investigating targeted therapies for SSc-ILD.
Main Methods:
- Review of recent clinical trial data and pathogenesis research in SSc-ILD.
- Synthesis of findings to inform best practices for study design.
- Formulation of expert recommendations for future research.
Main Results:
- Identification of key areas for improvement in SSc-ILD trial design.
- Emphasis on appropriate outcome measures and patient selection.
- Guidance on evaluating novel therapeutic strategies.
Conclusions:
- Optimized clinical trial design is crucial for advancing SSc-ILD treatment.
- Future studies should incorporate recent advances in understanding SSc-ILD pathogenesis.
- Recommendations aim to accelerate the development of effective therapies for SSc-ILD.
